JAK2 inhibitors for myeloproliferative neoplasms: what is next?
P Bose, S Verstovsek - Blood, The Journal of the American …, 2017 - ashpublications.org
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …
The critical role of inflammation in the pathogenesis and progression of myeloid malignancies
BM Craver, K El Alaoui, RM Scherber, AG Fleischman - Cancers, 2018 - mdpi.com
Hematopoietic stem cells (HSCs) maintain an organism's immune system for a lifetime, and
derangements in HSC proliferation and differentiation result in hematologic malignancies …
derangements in HSC proliferation and differentiation result in hematologic malignancies …
Emerging treatments for classical myeloproliferative neoplasms
AM Vannucchi, CN Harrison - Blood, The Journal of the …, 2017 - ashpublications.org
There has been a major revolution in the management of patients with myeloproliferative
neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly …
neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly …
[PDF][PDF] Myelofibrosis: clinicopathologic features, prognosis, and management
JM O'Sullivan, CN Harrison - Clin Adv Hematol Oncol, 2018 - hematologyandoncology.net
Myelofibrosis: Clinicopathologic Features, Prognosis, and Management Page 1 Clinical
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
Abstract JAK2V617F is the most common mutation in patients with BCR-ABL negative
myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem …
myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem …
JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
JM O'Sullivan, CN Harrison - Molecular and cellular endocrinology, 2017 - Elsevier
Myeloproliferative neoplasms (MPN) are a group of disorders defined by clonal proliferation
of mature myeloid cells with overlapping clinical features. The driver mutations of these …
of mature myeloid cells with overlapping clinical features. The driver mutations of these …
Second malignancies in hydroxyurea and interferon‐treated Philadelphia‐negative myeloproliferative neoplasms
IO Hansen, AL Sørensen… - European journal of …, 2017 - Wiley Online Library
Objective In an era of controversy in regard to 'hydroxyurea‐leukaemogenicity'and when
interferon‐alfa2 (IFN) is being revived in the treatment of Philadelphia‐negative …
interferon‐alfa2 (IFN) is being revived in the treatment of Philadelphia‐negative …
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies
JJ Kiladjian, P Guglielmelli, M Griesshammer… - Annals of …, 2018 - Springer
Ruxolitinib was well tolerated and superior to best available therapy (including interferon
[IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and …
[IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and …
Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib
ME Bjørn, HC Hasselbalch - Expert Review of Hematology, 2017 - Taylor & Francis
Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative
neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors …
neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors …
Polycythemia vera management and challenges in the community health setting
AT Gerds, KH Dao - Oncology, 2017 - karger.com
Patients with polycythemia vera (PV) experience shortened survival, increased risk of
thromboembolic and hemorrhagic events, and burdensome symptoms. For all patients with …
thromboembolic and hemorrhagic events, and burdensome symptoms. For all patients with …